Latest Breaking News On - Onset still - Page 1 : comparemela.com

Share this article Share this article The approval of Ilaris (canakinumab) in the treatment of adult-onset Still s disease (AOSD) brings hope for Canadians living with this rare, debilitating, and sometimes life-threatening inflammatory disorder. Ilaris, an interleukin-1 beta inhibitor, provides a new mode of treatment for this disease  which previously had limited options. 1,2 DORVAL, QC, April 29, 2021 /CNW Telbec/ - Novartis Pharmaceuticals Canada Inc. is pleased to announce that Health Canada has approved Ilaris ®  (canakinumab) for the treatment of active Still s disease, including adult-onset Still s disease (AOSD) 1. AOSD is a rare form of inflammatory arthritis that can be a complex disease with variable presentation and potentially life-threatening complications

Julie schneidermanDerek haalandAndrea marazziNovartis pharmaceuticals canadaNovartis pharmaceuticals canada incNovartis corporate communicationsHealth canadaPharmaceuticals canadaSystemic juvenile idiopathic arthritisCountry headNovartis pharmaceuticalsPeriodic fever syndromesCryopyric associated periodic syndromePharmaceuticals canada incClinical risk managementAdult onset still